Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pluvicto in mCRPC With Renal Impairment
NCT06004661Phase 2Active, not recruiting
- Sponsor
- Novartis
- Start
- Apr 2024
- Primary completion
- Dec 2026
- Modality
- Small Molecules, Peptide-Drug Conjugates
- Countries
- 5
01
Overview
A Phase 2 trial of lutetium lu 177 vipivotide tetraxetan in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Novartis. Started Apr 2024; status: active, not recruiting.
02
Drugs
lutetium lu 177 vipivotide tetraxetan
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT06004661.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06004661.